CV Sciences (CVSI) Net Income towards Common Stockholders (2011 - 2026)
CV Sciences (CVSI) reported Net Income towards Common Stockholders of -$643000.0 for Q1 2026, down 489.91% on a YoY basis from $164910.6 in Q1 2025, and down 499.38% sequentially from $161000.0 in Q4 2025.
CV Sciences (CVSI) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$643000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 489.91% year-over-year to -$643000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.1 million (up 30.3% YoY), and the FY2025 full-year result was -$591000.0, up 75.31% from the prior year.
- Net Income towards Common Stockholders eased to -$643000.0 in Q1 2026, from $161000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $5.7 million in Q1 2023 to a low of -$3.6 million in Q2 2022.
- A 5-year average of -$546882.4 and a median of -$584000.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders sank 2477.5% in 2022 and jumped 369.79% in 2023, its largest moves.
- Tracing CVSI's Net Income towards Common Stockholders over 5 years: stood at -$2.3 million in 2022, then surged by 62.43% to -$869000.0 in 2023, then soared by 46.49% to -$465000.0 in 2024, then surged by 134.62% to $161000.0 in 2025, then sank by 499.38% to -$643000.0 in 2026.
- Business Quant data shows CVSI's Net Income towards Common Stockholders at -$643000.0 in Q1 2026, $161000.0 in Q4 2025, and -$382000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -465,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -869,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -3.53 Mn |